Aromatase inhibition in advanced prostatic cancer: preliminary communication.

We report the results of the first use of a steroidal aromatase inhibitor, 4-hydroxyandrostenedione (4-OHA, CGP 32349), in the palliation of patients with advanced, hormone resistant, prostatic cancer. Twelve of 19 patients (63%), who had relapsed following castration and other therapies, gained sig...

Descripción completa

Detalles Bibliográficos
Autores principales: Shearer, R. J., Davies, J. H., Dowsett, M., Malone, P. R., Hedley, A., Cunningham, D., Coombes, R. C.
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1990
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1971817/
https://www.ncbi.nlm.nih.gov/pubmed/2201397
_version_ 1782134991862366208
author Shearer, R. J.
Davies, J. H.
Dowsett, M.
Malone, P. R.
Hedley, A.
Cunningham, D.
Coombes, R. C.
author_facet Shearer, R. J.
Davies, J. H.
Dowsett, M.
Malone, P. R.
Hedley, A.
Cunningham, D.
Coombes, R. C.
author_sort Shearer, R. J.
collection PubMed
description We report the results of the first use of a steroidal aromatase inhibitor, 4-hydroxyandrostenedione (4-OHA, CGP 32349), in the palliation of patients with advanced, hormone resistant, prostatic cancer. Twelve of 19 patients (63%), who had relapsed following castration and other therapies, gained significant pain relief following weekly intramuscular injections of 4-OHA. Five patients (31%) experienced a transient 'tumour flare', represented by an increase in bone pain soon after commencing treatment. The mechanism of action of 4-OHA in palliating patients with advanced prostatic cancer is obscure at present, but may represent an important new treatment modality which may lead to greater insight into prostatic biology.
format Text
id pubmed-1971817
institution National Center for Biotechnology Information
language English
publishDate 1990
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-19718172009-09-10 Aromatase inhibition in advanced prostatic cancer: preliminary communication. Shearer, R. J. Davies, J. H. Dowsett, M. Malone, P. R. Hedley, A. Cunningham, D. Coombes, R. C. Br J Cancer Research Article We report the results of the first use of a steroidal aromatase inhibitor, 4-hydroxyandrostenedione (4-OHA, CGP 32349), in the palliation of patients with advanced, hormone resistant, prostatic cancer. Twelve of 19 patients (63%), who had relapsed following castration and other therapies, gained significant pain relief following weekly intramuscular injections of 4-OHA. Five patients (31%) experienced a transient 'tumour flare', represented by an increase in bone pain soon after commencing treatment. The mechanism of action of 4-OHA in palliating patients with advanced prostatic cancer is obscure at present, but may represent an important new treatment modality which may lead to greater insight into prostatic biology. Nature Publishing Group 1990-08 /pmc/articles/PMC1971817/ /pubmed/2201397 Text en https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Research Article
Shearer, R. J.
Davies, J. H.
Dowsett, M.
Malone, P. R.
Hedley, A.
Cunningham, D.
Coombes, R. C.
Aromatase inhibition in advanced prostatic cancer: preliminary communication.
title Aromatase inhibition in advanced prostatic cancer: preliminary communication.
title_full Aromatase inhibition in advanced prostatic cancer: preliminary communication.
title_fullStr Aromatase inhibition in advanced prostatic cancer: preliminary communication.
title_full_unstemmed Aromatase inhibition in advanced prostatic cancer: preliminary communication.
title_short Aromatase inhibition in advanced prostatic cancer: preliminary communication.
title_sort aromatase inhibition in advanced prostatic cancer: preliminary communication.
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1971817/
https://www.ncbi.nlm.nih.gov/pubmed/2201397
work_keys_str_mv AT shearerrj aromataseinhibitioninadvancedprostaticcancerpreliminarycommunication
AT daviesjh aromataseinhibitioninadvancedprostaticcancerpreliminarycommunication
AT dowsettm aromataseinhibitioninadvancedprostaticcancerpreliminarycommunication
AT malonepr aromataseinhibitioninadvancedprostaticcancerpreliminarycommunication
AT hedleya aromataseinhibitioninadvancedprostaticcancerpreliminarycommunication
AT cunninghamd aromataseinhibitioninadvancedprostaticcancerpreliminarycommunication
AT coombesrc aromataseinhibitioninadvancedprostaticcancerpreliminarycommunication

Ejemplares similares